Disease · MONDO_0005404
myalgic encephalomeyelitis/chronic fatigue syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. myalgic encephalomeyelitis/chronic fatigue syndrome. Diseases, record MONDO_0005404. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005404
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- CFS, chronic fatigue immune dysfunction syndrome, chronic fatigue syndrome, myalgic encephalitis, myalgic encephalomyelitis, systemic exertion intolerance disease
- Open Targets
- Highest stage of its drugs
- Phase 3, for 3 of its 28 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs28
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| RINTATOLIMOD | CHEMBL2107862 | Phase 3 | ClinicalTrials.gov and TTD | 3 | 2 | 2 | Drugs and targets | |
| METFORMIN | CHEMBL1431 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ANAKINRA | CHEMBL1201570 | Protein | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DULOXETINE | CHEMBL1175 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NALTREXONE | CHEMBL19019 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CLONIDINE | CHEMBL134 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DROXIDOPA | CHEMBL2103827 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ETANERCEPT | CHEMBL1201572 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FERRIC CARBOXYMALTOSE | CHEMBL2108597 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 28
See all 28 drugsTargets109
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRA2A | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/152 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 3 | Norepinephrine transporter inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6530 | Drugs and targets |
| SLC6A4 | Sodium-dependent serotonin transporter | 3 | Serotonin transporter inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6532 | Drugs and targets |
| ACHE | Acetylcholinesterase | 1 | Acetylcholinesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/43 | Drugs and targets |
| ADRA1A | Adrenergic receptor | 1 | Adrenergic receptor agonist | Phase 2 | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor | 1 | Adrenergic receptor agonist | Phase 2 | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor | 1 | Adrenergic receptor agonist | Phase 2 | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRB1 | Adrenergic receptor | 1 | Adrenergic receptor agonist | Phase 2 | https://conductscience.org/library/genes/153 | Drugs and targets |
1 to 10 of 109
See all 109 targetsTrials25
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00375973 | Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome | Phase 2/3 | 60 | 2015-07-27 | Fatigue Syndrome, Chronic | DULOXETINE | Its record names the disease | ClinicalTrials.gov |
| NCT04141696 | A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue | Phase 1/2 | 10 | 2025-04-15 | Fatigue | KETAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT00977171 | Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome | Phase 2 | 3 | 2014-06-09 | Chronic Fatigue Syndrome, Orthostatic Hypotension, Neurally Mediated Hypotension, Neurogenic Orthostatic Hypotension | DROXIDOPA | Its record names the disease | ClinicalTrials.gov |
| NCT00215800 | The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome | Phase 3 | 234 | Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | RINTATOLIMOD | Its record names the disease | ClinicalTrials.gov | |
| NCT00580619 | Autonomic Nervous System and Chronic Fatigue Syndrome | Phase 1 | 170 | Chronic Fatigue Syndrome, Orthostatic Intolerance, Postural Tachycardia Syndrome | METHYLDOPA, TILARGININE, TRIMETHAPHAN | Its record names the disease | ClinicalTrials.gov | |
| NCT06366724 | LIFT: Life Improvement Trial | Phase 2 | 160 | ME/CFS, Long COVID, PASC | NALTREXONE, PYRIDOSTIGMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT02229942 | B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study. | Phase 3 | 151 | Chronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME) | RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01518634 | Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome | Phase 2 | 138 | Somatisation Disorder, Somatoform Disorders | IMIPRAMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01966276 | The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome | Phase 2 | 134 | Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis (ME) | METHYLPHENIDATE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01040429 | The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial | Phase 2 | 120 | Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | CLONIDINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 25
See all 25 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Duloxetine vs Placebo: Number of Participants Who Discontinued the Study for Any Reason | 10 of 30 | 2 of 30 | 60 | NCT00375973 | Trial comparisons |
| Duloxetine vs Placebo: Number of Participants Who Discontinued Use of Treatment Due to Adverse Events | 3 of 29 | 0 of 30 | 59 | NCT00375973 | Trial comparisons |
| Duloxetine vs Placebo: serious adverse events | 1 of 29 | 0 of 30 | 59 | NCT00375973 | Trial comparisons |
| Ketamine Administration vs Midazolam Administration: deaths from any cause | 0 of 8 | 0 of 8 | 16 | NCT04141696 | Trial comparisons |
| Ketamine Administration vs Midazolam Administration: serious adverse events | 0 of 8 | 0 of 8 | 16 | NCT04141696 | Trial comparisons |
Papers from its trials22
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005404
GET https://conductscience.org/api/diseases/v1/MONDO_0005404/drugs?page=2